Related Experiment Video

Updated: Jun 6, 2026

Phospholipid Mediator Induced Transformation in Three-Dimensional Cultures
08:02

Phospholipid Mediator Induced Transformation in Three-Dimensional Cultures

Published on: July 27, 2022

Phosphatase PRL-3 is a direct regulatory target of TGFbeta in colon cancer metastasis

Yanjun Jiang1, Xiao-Qiong Liu, Ashwani Rajput

  • 1University of Nebraska Medical Center, Eppley Institute for Research in Cancer and Allied Diseases, Omaha, Nebraska 68198, USA.

Cancer Research
|November 19, 2010
PubMed

Insights

Transforming growth factor beta (TGFβ) signaling suppresses colon cancer metastasis by inhibiting phosphatase of regenerating liver (PRL-3). Loss of TGFβ signaling activates PRL-3, promoting cancer cell survival and metastasis. PRL-3 antagonists may offer new antimetastatic therapies.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cell Signaling

Background:

  • Metastasis is the primary cause of cancer-related mortality, with limited therapeutic strategies.
  • Phosphatase of regenerating liver (PRL-3) overexpression correlates with colon cancer metastasis.
  • Transforming growth factor beta (TGFβ) signaling is crucial in cancer progression and metastasis.

Purpose of the Study:

  • To investigate the mechanistic link between TGFβ signaling, PRL-3, and colon cancer metastasis.
  • To elucidate the role of PRL-3 in TGFβ-mediated suppression of metastasis.
  • To explore the therapeutic potential of targeting PRL-3 in colon cancer.

Main Methods:

  • Analysis of TGFβ-mediated regulation of PRL-3 expression via Smad-dependent transcription.
  • Assessment of PRL-3's impact on PI3K/AKT signaling and apoptosis resistance.
  • Evaluation of PRL-3's role in colon cancer metastasis using an orthotopic mouse model.

Main Results:

  • TGFβ suppresses PRL-3 transcription, mediated by Smad signaling.
  • PRL-3 activation stimulates PI3K/AKT signaling, enhancing cell survival and apoptosis resistance.
  • PRL-3 overexpression promotes, while knockdown reduces, colon cancer metastasis, independent of primary tumor growth.

Conclusions:

  • Loss of TGFβ signaling activates PRL-3, driving a pro-metastatic cell survival pathway in colon cancer.
  • PRL-3 is a key mediator of TGFβ's antimetastatic effects.
  • PRL-3 antagonists represent a promising therapeutic strategy for colon cancer antimetastatic treatment.

More Related Videos

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells06:54

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells

Published on: October 27, 2020

Assessing Cellular Target Engagement by SHP2 (PTPN11) Phosphatase Inhibitors08:45

Assessing Cellular Target Engagement by SHP2 (PTPN11) Phosphatase Inhibitors

Published on: July 17, 2020

Related Concept Videos

TGF - β Signaling Pathway01:16

TGF - β Signaling Pathway

The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors are of three kinds RI, RII, and RIII. The RI...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
Amplifying Signals via Enzymatic Cascade01:22

Amplifying Signals via Enzymatic Cascade

When a ligand binds to a cell-surface receptor, the receptor's intracellular domain changes shape, which may either activate its enzyme function or allow its binding to other molecules. The initial signal is amplified by most signal transduction pathways. This means that a single ligand molecule can activate multiple molecules of a downstream target. Proteins that relay a signal are most commonly phosphorylated at one or more sites, activating or inactivating the protein. Kinases catalyze the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
IP3/DAG Signaling Pathway01:11

IP3/DAG Signaling Pathway

Membrane lipids such as phosphatidylinositol (PI) are precursors for several membrane-bound and soluble second messengers. Specific kinases phosphorylate PI and produce phosphorylated inositol phospholipids. One such inositol phospholipids are the  phosphatidylinositol-4,5 bisphosphate [PI(4,5)P2], present in the inner half of the lipid bilayer. Upon ligand binding, GPCR stimulates Gq proteins to turn on phospholipase Cꞵ. Activated phospholipase Cꞵ cleaves PI(4,5)P2 and produces two-second...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include: